



Science

VITAMIN D AND HIV INFECTION: THE CORRELATION & NEED FOR EVALUATION

Dr. Vandana Dabla ^{*1}, Dr. Ramesh Allam Reddy ²

^{*1} Project Officer-NISCHIT, CDC-SHARE INDIA, Society for Health Allied Research & Education (SHARE) India, MIMS Campus, Ghanpur Village, Medchal Mandal, Telangana, India

² Society for Health Allied Research & Education (SHARE) India, MIMS Campus, Ghanpur Village, Medchal Mandal, Telangana, India

Abstract

Background: India is the country with the third highest HIV disease burden globally. One of the most common long-term complications of HIV infection is bone diseases. There is prevalence of reduced bone mineral density (BMD) and thus higher risk of fragility fractures among PLHIV. Further, many HIV-positive cohorts suggest Vitamin-D hypovitaminosis exposing to osteopenia/osteoporosis in this population. This detailed review would provide an insight on correlation of Vitamin-D hypovitaminosis and HIV infection.

Material & Methods: A thorough review of published research studies and literature work was conducted. These studies were selected on the basis of data available on HIV seropositive population and Vitamin D in peer reviewed indexed journals. Both prospective and retrospective studies with or without control groups and randomized-controlled trials (RCTs) reporting baseline vitamin D status in HIV seropositive patients were included.

Results: We reviewed the association of vitamin D deficiency with HIV progression, mortality, and AIDS events, increased incidence and severity of Mycobacterium tuberculosis (TB) and hepatitis C virus (HCV) infection. Low bone mineral density (BMD) is a challenging metabolic condition in PLHIV. Further, the impact of antiretroviral drugs on vitamin D metabolism was studied. The effect of body index mass and non- and nucleoside reverse transcriptase inhibitors effects with hypovitaminosis D was further reviewed along with supplementation therapy of the vitamin and its effect in HIV positive population.

Conclusion: The optimal levels of 1,25(OH)Vitamin D is necessary for regulation of calcium and phosphorus balance for bone mineralization and remodelling. Without its adequate level in bloodstream; dietary calcium cannot be absorbed and thus causes a low BMD.

Keywords: HIV; PLHIV; Bone Mineral Density; 1,25(OH)Vitamin D; Mineralization.

Cite This Article: Dr. Vandana Dabla, and Dr. Ramesh Allam Reddy. (2019). “VITAMIN D AND HIV INFECTION: THE CORRELATION & NEED FOR EVALUATION.” *International Journal of Research - Granthaalayah*, 7(4), 68-82. <https://doi.org/10.5281/zenodo.2653114>.

1. Introduction

India is the country with the third highest HIV disease burden globally. The NACP is providing free antiretroviral therapy (ART) to more than 1.2 million PLHIV [1]. Since 2017, India adapted the routine viral load monitoring of treatment and Test & Treat policy. The rate of annual mortality since 2005 have significantly declined by almost 71% and the incidence of HIV infection also seen a decrease by 27% between 2010 and 2017 [2].

Increased life expectancy exposes People Living with HIV/AIDS (PLHIV) to chronic adverse drug reactions and to other age-related morbidities [3-5]. One of the most common long-term complications of HIV infection is bone diseases [6-8]. There is prevalence of reduced bone mineral density (BMD) and thus higher risk of fragility fractures among PLHIV [9-12]. Further, many HIV-positive cohorts suggest hypovitaminosis D exposing to osteopenia/osteoporosis in this population [13-19]. Additionally, the role of vitamin D can be also seen in non-skeletal functions, including cardiovascular and immune regulation, cancer prevention and brain health, apart from calcium homeostasis [20-24].

This detailed review would provide an insight on correlation of vitamin D hypovitaminosis and HIV infection, thus giving us a way to consider the significance of Vitamin D monitoring in PLHIV. We first briefly describe Vitamin D metabolism biological functions; then, we focus on the most recent epidemiological and experimental data dealing with the relationship between vitamin D deficiency and HIV infection. We analyse the extent of the problem, pathogenic mechanisms, clinical implications, and the potential effects of vitamin supplementation among PLHIV.

2. Methods

Selection Criterion & Data Analysis

A thorough review of published research studies and literature work was conducted. These studies were selected on the basis of data available on HIV seropositive population and Vitamin D in peer reviewed indexed journals. Both prospective and retrospective studies with or without control groups and randomized-controlled trials (RCTs) reporting baseline vitamin D status in HIV seropositive patients were included. Further, the search observed no geographical, language, race, age or gender restriction to consider wider distribution and outcome. However, Non-HIV seropositive group were excluded from review to prevent bias.

Vitamin D Metabolism

Vitamin D is a fat-soluble steroid, which is synthesized from a cholesterol precursor (7-dehydrocholesterol) [25]. The major forms of Vitamin D important to humans are Vitamin D₂(ergocalciferol) and Vitamin D₃ (cholecalciferol), synthesized from ergosterol in plants and naturally from cholesterol in animals respectively. These are available to body from the diet and Vitamin D-fortified products, among other sources [25,26].

However, the main source of Vitamin D for the human body is its synthesis in the skin. Cutaneous 7-dihydrocholesterol is converted into pre Vitamin D₃ following irradiation by ultraviolet (UV) light from the sun [26]. Then, by spontaneous isomerization of pre-Vitamin D₃ forms cholecalciferol (Vitamin D₃). Afterwards, Vitamin D₃ is hydroxylated to 25-hydroxy-Vitamin D

[25(OH)D] or calcidiol. This, 25(OH)D is then transported to kidneys, where it is hydroxylated to produce 1,25-dihydroxycholecalciferol [1,25 (OH)2D] or calcitriol. However, many other cell types can also produce 1,25(OH)2D and it is capable of regulating a wide variety of genes that are vital in regulating cell growth and differentiation.

The optimal levels of 1,25(OH)2D is necessary for regulation of calcium and phosphorus balance for bone mineralization and remodelling. Without its adequate level in bloodstream; dietary calcium cannot be absorbed and thus causes a low BMD. With its chronic deficiency in adults, there is greater risk of osteomalacia, osteoporosis, muscle weakness and increased risk of falls [26–33]. Thus, it is vital to maintain a normal level of vitD for skeletal benefits [27,28,34-36]. Moreover, vitamin D deficiency has also resulted in non-skeletal effects in many chronic diseases including, but not limited to, infectious diseases, autoimmune diseases, cardiovascular diseases, diabetes and cancer [34,37,38]. Further, research studies also correlate vitamin D deficiency with increased risk of developing tuberculosis [39,40], otitis media [41], upper respiratory tract infections [42] and influenza [43]. Thus, assessing for its levels is all the more important to avoid any such abnormality.

Investigation

The fastest way to measure Vitamin D levels in the body is the quantification of 25(OH)D in serum or plasma. However, this method has some drawbacks due to the hydrophobic nature of Vitamin D, its high affinity to Vitamin D binding protein (DBP), and the low concentration in blood (44). Plasma 25(OH)D or calcidiol (a summation of D3 and D2 forms) is the most reliable marker of vitamin D status. Immunoassays such as radioimmunoassay (RIA), enzyme linked immunosorbant assay (ELISA), chemiluminescence immunoassay and protein binding assays are used in routine testing of 25(OH)D in clinical laboratories. Liquid chromatography tandem mass spectrometry (LCTMS) is the widely accepted reference method for 25(OH)D measurement. However, LCTMS is tedious, expensive and time consuming and therefore seldom used commercially.

The measurement unit of Vitamin D levels are nanogram per milliliter (ng/mL) or nanomol/liter (nmol/L). Vitamin D deficiency in adults is considered to be when total 25(OH)D levels are <25 nmol/L (10 ng/mL) and inadequate/insufficient if levels are <75 nmol/L (30 ng/mL); while >75 nmol/L (30 ng/mL) is considered to be a normal healthy level [45, 46].

HIV and Deficiency of Vitamin D

Several research studies and trials were made since past to estimate prevalence of vitamin D deficiency among PLHIV [47]. Mansueti et al., presented that the prevalence of Vitamin D deficiency range from 70 to 85% in HIV-infected patients, based on a large number of epidemiological data of hypovitaminosis D with varying thresholds and a broad geo-localization of patients [48]. Studies had different range for assessing vitamin deficiency. Prevalence of hypovitaminosis with 25(OH)D levels be 10ng/mL, in 39.6% of HIV-infected patients [49]. Studies also observe correlation of hypovitaminosis D with nonskeletal conditions, including cardiovascular, immune regulation, cancer, and neurocognitive disorders [50-52]. Moreover, some studies suggest that severe vitamin D deficiency is associated with HIV progression, mortality, and AID Sevents [53], increased incidence and severity of Mycobacterium tuberculosis (TB) and hepatitis C virus (HCV) infection [48, 54].

Apart from many risk factors of vitamin D deficiency, as discussed above, the major risk factors among HIV infected population were associated with immune activation, chronic inflammation and antiretroviral treatment with potential interactions on the vitamin D metabolism[55-61]. In regards to other infectious diseases, Vitamin D levels have not been associated with better immune response to hepatitis B or pneumococcal vaccination in HIV-infected patients [62].

However, conflicting data has also been found of prevalence of Vitamin D deficiency among HIV infected compared to non-HIV infected individuals. Where one study described that Vitamin D deficiency was more prevalent in HIV-positive than in HIV-negative individuals [63], other found no such evidence [64].

Bone Turnover in Patients with HIV Infection

Low bone mineral density (BMD) is a challenging metabolic condition in PLHIV [65]. Amongst PLHIV with Vitamin D deficiency, it may have an abnormal bone turnover, such that a non-synchronisation of bone resorption and bone formation is observed with increased markers of bone resorption and stable or decreased markers of bone formation [66,67]. The presence of a chronic high bone turnover state may lead to reduced BMD.

Literature review highlighted the existence of many studies supporting high prevalence of osteopenia and osteoporosis in PLHIV. A meta-analysis showed prevalence of 67% of osteopenia and 15% of osteoporosis in PLHIV-. It further indicated that the rate of BMD reduction was 6.4-fold higher, and that of osteoporosis 3.7-fold higher in PLHIV [68]. Another study indicated that more than 50% of PLHIVs had osteopenia, and roughly 35% had osteoporosis [69]. A higher prevalence of fractures in PLHIVs, in comparison to HIV-negative patients is also reported by Triant et al [70].

Another cross-sectional cohort study by Bonjochet et al., of 671 PLHIV, indicated a high prevalence and considerable progression to osteopenia/osteoporosis. Their findings supported the importance of preventing bone demineralization and close monitoring of BMD in HIV-infected patients, specifically in at-risk patients who are on-ART (antiretroviral therapy) that affect bone mineralization. Their findings reported the rates for osteopenia and osteoporosis as 47.5% and 23% respectively, whilst BMD decreased in about 28% of patients in one 2.5 years of follow-up study[71]. Sharma et al., reported similar findings; where 42% and 12% PLHIVs were reported having osteopenia and osteoporosis respectively. The degree of osteopenia was three times higher compared with HIV negative subjects [72].

Vitamin D, Adaptive immunity and HIV infection

It is often challenging to establish a relationship between 25(OH)D levels, viral load and CD4+ T-cell count. Different mechanisms have been hypothesized to explain the association between 25(OH)D deficiency and severity of HIV disease.

Vitamin D may indirectly affect T-cell responses via modulation of the DC phenotype and its stimulatory capacity toward T cells [73]. The affect may also be observed on both naïve and resting memory T-cells [74]. T-cell activation increases the expression of VDR and CYP27B1, which allows 25(OH)D to be converted into 1,25(OH)₂D to modulate effector functions of Vitamin D [75].

Poowuttikul, Thomas et al., (2014) studied 160 HIV infected youth and found that severe low levels of vitamin D ($25(\text{OH})\text{D} \leq 10\text{ng/mL}$) was related to lower CD4 counts and lower CD4%; however, it was unrelated to HIV plasma RNA. He also stated that CD4 counts/ percentage had no effect upon vitamin supplementation. Very low vitamin D levels [$25(\text{OH})\text{D} \leq 10\text{ng/mL}$] was related to lower CD4 counts and CD4% but not to HIV plasma RNA. CD4 counts/CD4% did not increase under vitamin D supplementation [76].

Many studies suggested correlation between high HIV viral load and hypovitaminosis D in plasma [77-79]. Vitamin D deficiency is also found related to the decreased CD4+ T-cells in peripheral blood [80,81], rapid AIDS progression, and lower survival in HIV infected patients [82-86]. Such correlation of decreased CD4 T-cell count with higher prevalence of hypovitaminosis D is supported by many other studies [87,88,89]. However, literature review showed three, well-designed trials conducted on a large scale no such association between these two factors [89,90,91]. Among other HIV-related risk factors, inconsistent correlations were observed between HIV viral load, duration of ART treatment and duration of HIV infection [86,87,88,92,93,94].

Mortality rates were studied in 1103 PLHIVs for over 24 months at a research in Tanzania. The study revealed that $<20\text{ ng/mL}$ levels of $25(\text{OH})\text{D}$ was significantly associated with increased mortality as compared to $25(\text{OH})\text{D}$ levels of $>30\text{ng/mL}$. However, Vitamin D status was found unrelated to the changes in CD4 T-cell count after ART initiation [82].

Another analytical study in the larger EuroSIDA cohort also stated similar findings. Outcomes were compared of vitamin D tertiles of $<12\text{ ng/mL}$, 12.1 ng/mL to 20 ng/mL and $>20\text{ ng/mL}$. When compared PLHIVs in the lowest tertile with higher tertiles, it was found that the patients in former tertile had statistically significant greater risk for progression to AIDS and to death and a non-statistically significant increased risk for progression to non-AIDS-related events [95].

Hypovitaminosis D and Antiretroviral therapy

Several in vitro and in vivo studies and clinical trials tried to evaluate the impact of antiretroviral drugs on vitamin D metabolism. Both protease inhibitors (PIs) and non-nucleoside reverse transcriptase inhibitors (NNRTIs) have been long associated with the impairment of vitamin D metabolic pathways. Considering the major findings and research undertaken in large populations, only particular ART classes of drug were clearly found to be related to hypovitaminosis D [86,87,90]. Several authors demonstrated that (NNRTI) use was associated with $25(\text{OH})\text{D}$ deficiency [96-100].

A well designed cross-sectional assessment found that Serum $25(\text{OH})\text{D}$ was negatively correlated with body mass index, insulin resistance, HIV duration, and cumulative use of antiretroviral therapy, non- and nucleoside reverse transcriptase inhibitors. As refers to NNRTIs, for efavirenz (EFV) in particular, an association with low $25(\text{OH})\text{D}$ concentration has often been suggested due to compromised vitamin D homeostasis. EFV has been described indeed to increase $25(\text{OH})\text{D}$ catabolism, through the induction of CYP24 A_9 and reduced transcription of CYP2R1, a 25 -hydroxylase [97].

Pasquet et al., examined the association between decreased 25(OH)D and NNRTIs consumption, however he could not find any correlation with EFV and nevirapine (NVP). However, based on its regression models, he suggested a NNRTI class effect, rather than a specific EFV impact 25(OH)D levels [96]. Another study by Bovenet et al., [101] showed that vitamin D levels did not significantly change in comparison with baseline values among patients receiving the new NNRTI rilpivirine over 48 weeks, whereas a significant decrease was observed among those starting EFV-based regimen. Similarly, Allavena et al., [102] and Brown et al., [103] found decline in 25(OH)D serum levels after initiation of EFV-based regimen, in comparison with a non-EFV-based regimen.

On the contrary, one of the cross-sectional studies performed on 262 individuals, presented 25(OH)D levels as higher in patients exposed to NVP and PIs, in comparison with those exposed to EFV. Moreover, of the patients with baseline 25(OH)D insufficiency, a smaller proportion developed severe 25(OH)D deficiency with rilpivirine than EFV [104]. Similar but less consistent findings were observed for some nucleoside reverse transcriptase inhibitor (NRTIs), such as emtricitabine, tenofovir disoproxil fumarate (TDF) and zidovudine [87, 90, 105].

A small prospective observational study of 96 weeks, examined the consequence of ART regimen changes on vitamin D values, and demonstrated a beneficial effect (increase of 25OHD level) in switching from efavirenz (NNRTI) and/or zidovudine (NRTI) to darunavir/ ritonavir (PIs) [106]. However, one of the studies observed that patients who were prescribed TDF/EFV (NRTI/ NNRTI) did not have lower vitamin D levels [107].

A randomized 12 week controlled trial in HIV+ youth treated with TDF, assessed for effect of Vitamin D3 supplementation on fibroblast growth factor-23 (FGF-23). The findings clearly indicated an increase in the fibroblast growth factor 23 (FGF23) response to vitamin D supplementation in HIV-infected youth. The findings were supported by similar studies in vitamin D-deficient PLHIVs treated with TDF, where open-label vitamin D supplementation was associated with a trend toward increased FGF23 [108], in contrast to what was observed in non-HIV infected persons with vitamin D deficiency [109].

Additionally, different studies associate vitamin D and TDF-linked hyperparathyroidism, emphasizing that both influence in PTH values. One of the studies suggests that the increased hydroxylation rates and tubular phosphate losses, which drive calcium preservation and possibly altered bone metabolism, are dependent on vitamin D status [110]. Moreover PTH elevations have been observed in patients taking both NNRT and PI [111-113]. Results for PIs suggested a protective effect against hypovitaminosis D [87, 91, 95].

Supplementation of vitamin D

In the general population, current recommended dietary allowances (RDA) of vitamin D are 700-800 IU cholecalciferol/day [55]. Serum 25(OH)D levels generally increase by approximately 1 ng/ml for every 100 IU of vitamin D intake [114]. However, efficacy of vitamin D repletion in PLHIVs is evaluated through few small cohorts studies. Some clinical trials assessing Vitamin D supplementation have demonstrated a positive impact on BMD in subgroups of PLHIVs who were initiating ART or on suppressive ART regimens. However, significant heterogeneity exists between studies; and data are less consistent with other clinical outcomes.

Van den Bout et al., treated 20 vitamin D deficient PLHIVs with 2000 IU cholecalciferol/day for 14 weeks, after which the dosage was lowered to 1000 IU/day until 48 weeks. The evaluation of 25(OH)D₃ and 1,25(OH)₂D₃ levels at 24 weeks showed normalized values, but after 48 weeks only serum 25(OH)D₃ was significantly different from baseline, whereas 1,25(OH)₂D₃ returned to baseline levels, probably because of the reduction in cholecalciferol dose [115].

Arpadiet al., reported the benefits of oral doses (twice in a month) of 100,000 IU cholecalciferol and 1g/day calcium in a cohort of HIV-infected children and adolescents during a year long study. In this study, 25(OH)D levels were found significantly higher among supplemented subjects, in comparison with individuals receiving placebo; 44.4% of subjects in the group receiving cholecalciferol and calcium had 25(OH)D > 30 ng/ml after 1 year [93]. Similarly, Havens et al., studied a cohort of 207 PLHIVs, when orally administering vitamin D₃ (50000 IU in three doses at monthly intervals) showed a rapid increase in 25(OH)D serum concentration [116].

A well designed controlled study in India, evaluates the relationship between vitamin-D, zinc and copper supplementation and the CD4 counts in HIV-positive mothers. The study was conducted for three year period, where 195 HIV-positive antenatal cases were studied for effect of vitamin D supplementation and other mineralson CD4 count. The first group of 49 cases were evaluated for CD4 count at their first visit to facility, then received 400 I.U/day of vitamin-D supplementation and re-evaluated at 36 weeks of gestation and at six weeks post-partum, irrespective of the outcome of pregnancy. Significant improvement in CD4 counts was observed in the group where Vitamin D supplementation was given as compared to the control. Thus, the study established a significant relationship of improved CD4 counts with vitamin D supplementation [117].

Another rdouble-blind, placebo-controlled study of 48 weeks evaluated the effect of high dose vitamin D₃ (4000 IU daily) plus calcium supplementation (1000 mg calcium carbonate daily) on BMD in HIV-infected subjects initiating ART with efavirenz/emtricitabine/tenofovir. The primary endpoint was percentage change in total hip BMD over 48 weeks. Results showed that vitamin D/calcium supplementation mitigated the loss of BMD seen with initiation of efavirenz/emtricitabine/tenofovir, particularly at the total hip [118].

Further, another study concluded that vitamin D supplementation in HIV-infected patients is safe and valid for correcting vitaminD abnormalities and to improve raised PTH levels, but not enough for normalizing them, especially in patients exposed to tenofovir or protease inhibitors [119]. However, others did not find that vitamin D (in any possible formula) supplementation can increase CD4+ count [120,121]. One of the research studies pointed out, that only 40% of patients receiving oral vitamin D supplements had 25(OH)D levels >30 ng/ml after a median 16 week follow up. Supporting this claim, one of the studies showed only 46% reduction in hypovitaminosis D was observed in a cohort of HIV-positive young adults receiving 50000 IU vitamin D₃/week for 12 weeks [122].

Although arguments may be found against wide spread screening for vitamin D deficiency in HIV-infected patients, it include the unclear benefit of vitamin D replacement for non-musculoskeletal outcomes with potential toxicities of some supplementation approaches [123]. The optimal repletion and maintenance dosing regimens remain to be established as well as the impact of vitamin D supplementation in preventing comorbidities [124].

3. Conclusion

Vitamin D deficiency is emerging as a matter of great concern among HIV-infected population. Although no clear consensus have been reached on its effect on the life expectancy of PLHIVs, given the overlapping risk for potential chronic diseases and immune-modulatory impact from both HIV infection and Vitamin D deficiency; the clinical role of Vitamin D for this population needs attention and further assessment. Also, given the widespread presence of this deficiency in PLHIV, the benefit of screening vitamin D deficiency and its replacement needs a systematic evaluation.

References

- [1] India HIV Estimation 2017, Fact Sheet. National AIDS Control Organization & ICMR-National Institute of Medical Statistics. Ministry of Health & Family Welfare. Government of India.
- [2] India HIV Estimation 2017, Technical Report. National AIDS Control Organization & ICMR-National Institute of Medical Statistics. Ministry of Health & Family Welfare. Government of India.
- [3] S. G. Deeks, S. R. Lewin, and D. V. Havlir, "The end of AIDS: HIV infection as a chronic disease," *The Lancet*, vol. 382, no. 9903, pp.1525–1533,2013.
- [4] J.E.Lakeand, J.S.Currier, "MetabolicdiseaseinHIVinfection," *The Lancet Infectious Diseases*, vol.13, no.11, pp.964–975, 2013.
- [5] V.A.Triant,"CardiovasculariseaseandHIVinfection,"*CurrentHIV/AIDSReports*,vol.10,no.3,pp.199–206,2013.
- [6] Stone B, Dockrell D, Bowman C, MccloskeyE. HIV and bone disease. *Arch Biochem Biophys* 2010; 503:66-77.
- [7] KnobelH, GuelarA, VallecilloG, NoguesX, DiezA. Osteopenia in HIV-infected patients: is it the disease or is it the treatment? *AIDS* 2001; 15: 807-808.
- [8] CazanaveC, DuponM, Lavignolle-Aurillac V, BartheN, Lawson-Ayayi S et al., Groupe D'epidemiologie Clinique Du Sida En Aquitaine. Reduced bone mineral density in HIV-infected patients: prevalence and associated factors. *AIDS* 2008; 22: 395-402.
- [9] Tebas P, Powderly Wg, Claxton S, Marin D, Tantisiriwat W, TeitelbaumSI, YarasheskiKe. Accelerated bone mineral loss in HIV-infected patients receiving potent antiretroviral therapy. *AIDS* 2000; 14: F63-67.
- [10] Brown Tt, QaqishRb. Antiretroviral therapy and the prevalence of osteopenia and osteoporosis: a meta-analytic review.*AIDS* 2006;20:2165-2174.
- [11] TriantVa, Brown Tt, Lee H, Grinspoon Sk. Fracture prevalence among human immunodeficiency virus (HIV)-infected versus non-HIV-infected patients in a large U.S. healthcare system. *J ClinEndocrinolMetab* 2008;93:3499-3504.
- [12] Calmy A, FuxCa, Norris R, Vallier N, Delhumeau C, Samaras K, Hesse K, Hirschel B, Cooper Da, Carr A. Low bone mineral density, renal dysfunction, and fracture risk in HIV infection: a cross-sectional study.*J Infect Dis* 2009;200:1746-1754
- [13] Overton Et, Mondy K, Bush T. Factors Associated with Low Bone Mineral Density in a Large Cohort of HIV-infected US Adults: Baseline Results from the SUN Study. *Proceedings of the 14th Conference on Retroviruses and Opportunistic Infections 2007*. Los Angeles, CA:Abstract 836.
- [14] ArnstenJh, Freeman R, Howard Aa, Florismoore M, Lo Y, Klein Rs. Decreased bone mineral density and increased fracture risk in aging men with or at risk for HIV infection. *AIDS* 2007; 21: 617-623.
- [15] Stein Em, Yin Mt, McMahanDj, Shu A, Zhang Ca, Ferris Dc, Colon I, DobkinJf , Hammer Sm, Shane E. Vitamin D deficiency in HIV-infected postmenopausal Hispanic and African-American women.*OsteoporosInt* 2010;22:477-487.

- [16] Yin Mt, Lu D, Cremers S, Tien Pc, Cohen Mh, Shi Q, Shane E, Golub Et, Anastos K. Short-term bone loss in HIV-infected premenopausal women. *J Acquir Immune Defic Syndr* 2010;53:202-208.
- [17] Seminari E, Castagna A, Soldarini A, Galli L, Fusetti G, Dorigatti F, Hasson H, Danise A, Guffanti M, Lazzarin A, Rubinacci A. Osteoprotegerin and bone turnover markers in heavily pretreated HIV-infected patients. *HIV Med* 2005;6:145-150.
- [18] Garcia Aparicio Am, FernándezSm, González J, ArribasJr, Peña Jm, VázquezJj, Martínez Me, CoyaJ, MartínMola E. Abnormalities in the bone mineral metabolism in HIV-infected patients. *Clin Rheumatol* 2006;25:537-539.
- [19] Teichmann J, Stephan E, Lange U, Discher T, Friese G, Lohmeyer J, Stracke H, BretzelRg. Osteopenia in HIV infected women prior to highly active antiretroviral therapy. *J Infect* 2003; 46: 221-227.
- [20] Bikle D. Nonclassic actions of vitamin D. *J Clin Endocrinol Metab* 2009; 94: 26-34.
- [21] Di Rosa M, Malaguarnera G, De Gregorio C, Palumbo M, Nunnari G, Malaguarnera L. Immunomodulatory effects of vitamin D3 in human monocyte and macrophages. *Cell Immunol* 2012; 280: 36-43.
- [22] Di Rosa M, Malaguarnera L, Nicolosi A, Sanfilippo C, Mazzarino C, Pavone P, Berretta M, Cosentino S, Cacopardo B, Pinzone Mr, NunnariG. Vitamin D3: an ever green molecule. *Front Biosci (Schol Ed)* 2013;5:247-260.
- [23] Nunnari g, coco c, pinzonemr, pavone p, berretta m, di rosa m, schnell m, calabrese g, cacopardo b. The role of micronutrients in the diet of hiv1-infected individuals. *front biosci (elite ed)* 2012;4:2442-2456.
- [24] CacopardoB, CammaC, PettaS, PinzoneMR, CappellaniA, ZanghiA, NicolosiA, Nunnari G. Diagnostic and therapeutical role of vitamin D in chronic hepatitis C virus infection. *Front Biosci (Elite Ed)*.2012;4:1276-1286.
- [25] Herrmann M, Farrell CL, Pusceddu I, Fabregat-Cabello N, Cavalier E. Assessment of vitamin D status – a changing landscape. *Clin Chem Lab Med* (2017) 55(1):3–26. doi:10.1515/cclm-2016-0264
- [26] Dusso AS, Brown AJ, Slatopolsky E. Vitamin D. *Am J Physiol Renal Physiol* (2005) 289(1):F8–28. doi:10.1152/ajprenal.00336.2004
- [27] Hazell, T.J.; DeGuire, J.R.; Weiler, H.A. Vitamin D: An overview of its role in skeletal muscle physiology in children and adolescents. *Nutr. Rev.* 2012, 70, 520–533.
- [28] Holick, M.F. The role of vitamin D for bone health and fracture prevention. *Curr. Osteoporos. Rep.* 2006, 4, 96–102. 6. Lips, P.; van Schoor, N.M. The effect of vitamin D on bone and osteoporosis. *Best Pract. Res. Clin. Endocrinol. Metab.* 2011, 25, 585–591.
- [29] Janssen, H.C.; Samson, M.M.; Verhaar, H.J. Vitamin D deficiency, muscle function, and falls in elderly people. *Am. J. Clin. Nutr.* 2002, 75, 611–615.
- [30] Bischoff, H.A.; Stahelin, H.B.; Urscheler, N.; Ehram, R.; Vonthein, R.; Perrig-Chiello, P.; Tyndall, A.; Theiler, R. Muscle strength in the elderly: Its relation to vitamin D metabolites. *Arch. Phys. Med. Rehabil.* 1999, 80, 54–58.
- [31] Bischoff-Ferrari, H.A.; Dawson-Hughes, B.; Willett, W.C.; Staehelin, H.B.; Bazemore, M.G.; Zee, R.Y.; Wong, J.B. Effect of Vitamin D on falls: A meta-analysis. *JAMA* 2004, 291, 1999–2006.
- [32] Bischoff-Ferrari, H.A.; Dietrich, T.; Orav, E.J.; Dawson-Hughes, B. Positive association between 25-hydroxy vitamin D levels and bone mineral density: A population-based study of younger and older adults. *Am. J. Med.* 2004, 116, 634–639.
- [33] Bischoff-Ferrari, H.A.; Zhang, Y.; Kiel, D.P.; Felson, D.T. Positive association between serum 25-hydroxyvitamin D level and bone density in osteoarthritis. *Arthritis Rheum.* 2005, 53, 821–826.
- [34] Thacher, T.D.; Clarke, B.L. Vitamin D insufficiency. *Mayo Clin. Proc.* 2011, 86, 50–60.
- [35] Murad, M.H.; Elamin, K.B.; Abu Elnour, N.O.; Elamin, M.B.; Alkatib, A.A.; Fatourechi, M.M.; Almandoz, J.P.; Mullan, R.J.; Lane, M.A.; Liu, H.; et al., Clinical review: The effect of vitamin D on falls: A systematic review and meta-analysis. *J. Clin. Endocrinol. Metab.* 2011, 96, 2997–3006.

- [36] Lips, P. Worldwide status of vitamin D nutrition. *J. Steroid Biochem. Mol. Biol.* 2010, 121, 297–300.
- [37] Pilz, S.; Tomaschitz, A.; Marz, W.; Drechsler, C.; Ritz, E.; Zittermann, A.; Cavalier, E.; Pieber, T.R.; Lappe, J.M.; Grant, W.B.; et al., Vitamin D, cardiovascular disease and mortality. *Clin. Endocrinol.* 2011, 75, 575–584.
- [38] Haines, S.T.; Park, S.K. Vitamin D supplementation: What’s known, what to do, and what’s needed. *Pharmacotherapy* 2012, 32, 354–382
- [39] Nnoaham, K.E.; Clarke, A. Low serum vitamin D levels and tuberculosis: A systematic review and meta-analysis. *Int. J. Epidemiol.* 2008, 37, 113–119.
- [40] Martineau, A.R. Old wine in new bottles: Vitamin D in the treatment and prevention of tuberculosis. *Proc. Nutr. Soc.* 2012, 71, 84–89.
- [41] Linday, L.A.; Shindledecker, R.D.; Dolitsky, J.N.; Chen, T.C.; Holick, M.F. Plasma 25-hydroxyvitamin D levels in young children undergoing placement of tympanostomy tubes. *Ann. Otol. Rhinol. Laryngol.* 2008, 117, 740–744.
- [42] Ginde, A.A.; Mansbach, J.M.; Camargo, C.A., Jr. Association between serum 25-hydroxyvitamin D level and upper respiratory tract infection in the Third National Health and Nutrition Examination Survey. *Arch. Intern. Med.* 2009, 169, 384–390.
- [43] Cannell, J.J.; Vieth, R.; Umhau, J.C.; Holick, M.F.; Grant, W.B.; Madronich, S.; Garland, C.F.; Giovannucci, E. Epidemic influenza and vitamin D. *Epidemiol. Infect.* 2006, 134, 1129–1140
- [44] Hollis BW. Assessment and interpretation of circulating 25-hydroxyvitamin D and 1,25-dihydroxy vitamin D in the clinical environment. *EndocrinolMetabClin North Am* (2010) 39(2):271–86. doi:10.1016/j.ecl.2010.02.012
- [45] Holick MF. Vitamin D status: measurement, interpretation, and clinical application. *Ann Epidemiol* (2009) 19(2):73–8. doi:10.1016/j.annepidem.2007.12.001
- [46] SACoN (SACN). Update on Vitamin D: Position Statement by the Scientific Advisory Committee on Nutrition (2007).
- [47] M. R. Pinzone, M. di Rosa, M. Malaguarnera et al., “Vitamin D deficiency in HIV infection: an underestimated and undertreated epidemic” *Medical and Pharmacological Sciences*, vol.17, no.9, pp.1218–1232,2013.
- [48] Mansueto P, Seidita A, Vitale G, Gangemi S, Iaria C, Cascio A. Vitamin D deficiency in HIV infection: not only a bone disorder. *Biomed Res Int* (2015) 2015:735615. doi:10.1155/2015/735615
- [49] E. Lerma, M. E. Molas, M. M. Montero et al., “Prevalence and factors associated with vitamin D deficiency and hyperparathyroidism in HIV-infected patients treated in Barcelona,” *ISRN AIDS*, vol.2012, Article ID485307, 5 pages, 2012.
- [50] D. Bikle, “Non classic actions of vitamin D,” *The Journal of Clinical Endocrinology & Metabolism*, Vol.94, pp.26–34, 2009.
- [51] T.Ansemant,S.Mahy,C.Pirothetal.,“Severehypovitaminosis D correlates with increased inflammatory markers in HIV infectedpatients,”*BMCInfectiousDiseases*,vol.13,no.1,article 7,2013.
- [52] A. Conesa-Botella, C. Mathieu, R. Colebunders et al., “Is vitamin D deficiency involved in the immune reconstitution inflammatory syndrome?” *AIDS Research and Therapy*, vol. 6, article4,2009.
- [53] J.-P. Viard, J.-C. Souberbielle, O. Kirk et al., “Vitamin D and clinical disease progression in HIV infection: Results from the EuroSIDA Study,” *AIDS*, vol.25, no.10, pp.1305–1315, 2011.
- [54] Lucas RM, Gorman S, Geldenhuys S, Hart PH. Vitamin D and immunity. *F1000Prime Rep* (2014) 6:118. doi:10.12703/P6-118.
- [55] Penna G, Adorini L. 1 alpha,25-dihydroxyvitamin D3 inhibits differentiation, maturation, activation, and survival of dendritic cells leading to impaired alloreactive T cell activation. *J Immunol* (2000) 164(5):2405–11. doi:10.4049/jimmunol.164.5.2405.

- [56] Pedersen AW, Holmstrom K, Jensen SS, Fuchs D, Rasmussen S, Kvistborg P, et al., Phenotypic and functional markers for 1 α ,25-dihydroxyvitamin D(3)-modified regulatory dendritic cells. *ClinExpImmunol* (2009) 157(1):48–59. doi:10.1111/j.1365-2249.2009.03961.x
- [57] Unger WW, Laban S, Kleijwegt FS, van der Slik AR, Roep BO. Induction of Treg by monocyte-derived DC modulated by vitamin D3 or dexamethasone: differential role for PD-L1. *Eur J Immunol* (2009) 39(11):3147–59. doi:10.1002/eji.200839103
- [58] Van Etten E, Dardenne O, Gysemans C, Overbergh L, Mathieu C. 1,25-dihydroxyvitamin D3 alters the profile of bone marrow-derived dendritic cells of NOD mice. *Ann N Y AcadSci* (2004) 1037:186–92. doi:10.1196/annals.1337.030
- [59] Ferreira GB, Gysemans CA, Demengeot J, da Cunha JP, Vanherwegen AS, Overbergh L, et al., 1,25-dihydroxyvitamin D3 promotes tolerogenic dendritic cells with functional migratory properties in NOD mice. *J Immunol* (2014) 192(9):4210–20. doi:10.4049/jimmunol.1302350
- [60] Penna G, Amuchastegui S, Giarratana N, Daniel KC, Vulcano M, Sozzani S, et al., 1,25-dihydroxyvitamin D3 selectively modulates tolerogenic properties in myeloid but not plasmacytoid dendritic cells. *J Immunol* (2007) 178(1):145–53. doi:10.4049/jimmunol.178.1.145
- [61] Alroy I, Towers TL, Freedman LP. Transcriptional repression of the interleukin-2 gene by vitamin D3: direct inhibition of NFATp/AP-1 complex formation by a nuclear hormone receptor. *Mol Cell Biol* (1995) 15(10):5789–99. doi:10.1128/MCB.15.10.5789
- [62] Viard JP, Assuied A, Levy Y, Souberbielle JC, Thiebaut R, Carrat F, et al. No positive association between vitamin D level and immune responses to hepatitis B and Streptococcus pneumoniae vaccination in HIV-infected adults. *PLoS One* (2016) 11(12):e0168640. doi:10.1371/journal.pone.0168640.
- [63] Cervero M, Agud JL, Garcia-Lacalle C, Alcazar V, Torres R, Jurdado JJ, et al., Prevalence of vitamin D deficiency and its related risk factor in a Spanish cohort of adult HIV-infected patients: effects of antiretroviral therapy. *AIDS Res Hum Retroviruses* (2012) 28(9):963–71. doi:10.1089/AID.2011.0244
- [64] Orkin C, Wohl DA, Williams A, Deckx H. Vitamin D deficiency in HIV: a shadow on long-term management? *AIDS Rev* (2014) 16(2):59–74.
- [65] Enock MC, Demitri C, Fanuel L. Management of Reduced Bone Mineral Density in HIV: Pharmacological Challenges and the Role of Exercise. *Frontiers in Physiology*, 2018, Article 1074, Volume 9.
- [66] Mondy K, Yarasheski K, Powderly WG, et al.: Longitudinal evolution of bone mineral density and bone markers in human immunodeficiency virus-infected individuals. *Clin Infect Dis* 2003, 36:482–490. One of the first longitudinal studies of BMD in patients with HIV infection. Also, one of the only studies to have bone biopsy data.
- [67] Brown TT, Ruppe MD, Kassner R, et al.: Reduced bone mineral density in human immunodeficiency virus-infected patients and its association with increased central adiposity and postloadhyperglycemia. *J ClinEndocrinolMetab* 2004, 89:1200–1206.
- [68] Brown TT, Qaqish RB. Antiretroviral therapy and the prevalence of osteopenia and osteoporosis: a meta-analytical review. *AIDS*. 2006;20:2165–74.
- [69] Cazanave C, Dupon M, Lavignolle-Aurillac V, Barthe N, Lawson-Ayayi S, Mehse N, et al. Reduced bone mineral density in HIV-infected patients: prevalence and associated factors. *AIDS*. 2008;22(3):395–402.
- [70] Triant VA, Brown TT, Lee H, Grinspoon SK. Fracture prevalence among human immunodeficiency virus (HIV)-infected versus non-HIV-infected patients in a large U.S. healthcare system. *J ClinEndocrinolMetab*. 2008;93(9):3499–504.
- [71] Bonjoch A, Figueras M, Estany C, Perez-Alvarez N, Rosales J, del Rio L, et al. High prevalence of and progression to low bone mineral density in HIV-infected patients: a longitudinal cohort study. *AIDS*. 2010;24:2827–33.
- [72] Sharma A, Flom PL, Weedon J, Klein RS. Prospective study of bone mineral density changes in aging men with or at risk for HIV infection. *AIDS*. 2010;24(15):2337–45.

- [73] Vanherwegen AS, Gysemans C, Mathieu C. Vitamin D endocrinology on the cross-road between immunity and metabolism. *Mol Cell Endocrinol* (2017) 453:52–67. doi:10.1016/j.mce.2017.04.018.
- [74] Sigmundsdottir H, Pan J, Debes GF, Alt C, Habtezion A, Soler D, et al. DCs metabolize sunlight-induced vitamin D3 to 'program' T cell attraction to the epidermal chemokine CCL27. *Nat Immunol* (2007) 8(3):285–93. doi:10.1038/ni1433.
- [75] Baeke F, Korf H, Overbergh L, Van Etten E, et al. Human T lymphocytes are direct targets of 1,25-dihydroxyvitamin D3 in the immune system. *J Steroid BiochemMolBiol* (2010) 121(1–2):221–7. doi:10.1016/j.jsbmb.2010.03.037.
- [76] Poowuttikul P, Thomas R, Hart B, Secord E. Vitamin D Insufficiency/Deficiency in HIV-Infected Inner City Youth. *J IntAssocProvid AIDS Care*. 2014 Sep-Oct;13(5):438-42. doi: 10.1177/2325957413495566. Epub 2013 Jul 23.
- [77] Flauzino T, Simao ANC, de Almeida ERD, Morimoto HK, Oliveira SR, Alfieri DF, et al. Association between vitamin D status, oxidative stress biomarkers and viral load in human immunodeficiency virus type 1 infection. *Curr HIV Res* (2017) 15(5):336–44. doi:10.2174/1570162X15666171005170227.
- [78] Coussens AK, Naude CE, Goliath R, Chaplin G, Wilkinson RJ, Jablonski NG. High-dose vitamin D3 reduces deficiency caused by low UVB exposure and limits HIV-1 replication in urban Southern Africans. *ProcNatlAcadSci U S A* (2015) 112(26): 8052–7. doi:10.1073/pnas.1500909112.
- [79] Bearden A, Abad C, Gangnon R, Sosman JM, Binkley N, Safdar N. Crosssectional study of vitamin D levels, immunologic and virologic outcomes in HIV-infected adults. *J ClinEndocrinolMetab* (2013) 98(4):1726–33. doi:10.1210/jc.2012-4031.
- [80] Theodorou M, Serste T, Van Gossum M, Dewit S. Factors associated with vitamin D deficiency in a population of 2044 HIV-infected patients. *ClinNutr* (2014) 33(2):274–9. doi:10.1016/j.clnu.2013.04.018.
- [81] Coelho L, Cardoso SW, Luz PM, Hoffman RM, Mendonca L, Veloso VG, et al. Vitamin D3 supplementation in HIV infection: effectiveness and associations with antiretroviral therapy. *Nutr J* (2015) 14:81. doi:10.1186/s12937-015-0072-6.
- [82] Sudfeld CR, Wang M, Aboud S, Giovannucci EL, Mugusi FM, Fawzi WW. Vitamin D and HIV progression among Tanzanian adults initiating antiretroviral therapy. *PLoS One* (2012) 7(6):e40036. doi:10.1371/journal.pone.0040036.
- [83] Mehta S, Giovannucci E, Mugusi FM, Spiegelman D, Aboud S, Hertzmark E, et al. Vitamin D status of HIV-infected women and its association with HIV disease progression, anemia, and mortality. *PLoS One* (2010) 5(1):e8770. doi:10.1371/journal.pone.0008770.
- [84] Haug C, Muller F, Aukrust P, Froland SS. Subnormal serum concentration of 1,25-vitamin D in human immunodeficiency virus infection: correlation with degree of immune deficiency and survival. *J Infect Dis* (1994) 169(4):889–93. doi:10.1093/infdis/169.4.889.
- [85] Shepherd L, Souberbielle JC, Bastard JP, Fellahi S, Capeau J, Reekie J, et al. Prognostic value of vitamin D level for all-cause mortality, and association with inflammatory markers, in HIV-infected persons. *J Infect Dis* (2014) 210(2):234–43. doi:10.1093/infdis/jiu074.
- [86] Stein EM, Yin MT, McMahon DJ, Shu A, Zhang CA, Ferris DC, Colon I, Dobkin JF, Hammer SM, Shane E. Vitamin D deficiency in HIV-infected postmenopausal Hispanic and African-American women. *OsteoporosInt* 2010;22:477-487.
- [87] Adeyemi OM, Agniel D, French AL, et al. Vitamin D deficiency in HIV-infected and uninfected women in the US. *J Acquir Immune Defic Syndr*. 2011;57(3):197–204.
- [88] Ross AC, Judd S, Kumari M, et al. Vitamin D is linked to carotid intimamedia thickness and immune reconstitution in HIV-positive individuals. *AntivirTher*. 2011;16(4):555–563.
- [89] Milazzo L, Mazzali C, Bestetti G, et al. Liver-related factors associated with low vitamin D levels in HIV and HIV/HCV coinfecting patients and comparison to general population. *Curr HIV Res*. 2011;9(3): 186–193.

- [90] Dao CN, Patel P, Overton ET, et al. Low vitamin D among HIV-infected adults: prevalence of and risk factors for low vitamin D Levels in a cohort of HIV-infected adults and comparison to prevalence among adults in the US general population. *Clin Infect Dis.* 2011;52(3):396–405.
- [91] Mehta S, Spiegelman D, Aboud S, et al. Lipid-soluble vitamins A, D, and E in HIV-infected pregnant women in Tanzania. *Eur J Clin Nutr.* 2010;64(8):808–817
- [92] Mehta S, Mugusi FM, Spiegelman D, Villamor E, Finkelstein JL, Hertzmark E, Giovannucci EL, Msamanga GI, Fawzi WW. Vitamin D status and its association with morbidity including wasting and opportunistic illnesses in HIV-infected women in Tanzania. *AIDS Patient Care STDS* 2011; 25: 579-585.
- [93] Arpadi SM, McMohan D, Abrams EJ, Bamji M, Purswani M, Engelson ES, Horlick M, Shane E. Effect of bimonthly supplementation with oral cholecalciferol on serum 25-hydroxyvitamin D concentrations in HIV-infected children and adolescents. *Pediatrics* 2009; 123: e121-126.
- [94] Mehta S, Giovannucci E, Mugusi FM, Spiegelman D, Aboud S, Hertzmark E, Msamanga GI, Hunter D, Fawzi WW. Vitamin D status of HIV-infected women and its association with HIV disease progression, anemia, and mortality. *PLoS One* 2010; 5: e8770.
- [95] Viard JP, Souberbielle JC, Kirk O, et al. Vitamin D and clinical disease progression in HIV infection: results from the EuroSIDA study. *AIDS.* 2011;25(10):1305-1315.
- [96] Pasquet A, Viget N, Ajana F, et al. Vitamin D deficiency in HIV-infected patients: associated with non-nucleoside reverse transcriptase inhibitor or efavirenz use? *AIDS.* 2011;25(6):873–874.
- [97] Conesa-Botella A, Florence E, Lynen L, Colebunders R, Menten J, Moreno-Reyes R. Decrease of vitamin D concentration in patients with HIV infection on a non nucleoside reverse transcriptase inhibitor containing regimen. *AIDS Res Ther.* 2010;7:40.
- [98] Mueller NJ, Fux CA, Ledergerber B, et al. High prevalence of severe vitamin D deficiency in combined antiretroviral therapy-naive and successfully treated Swiss HIV patients. *AIDS.* 2010;24(8):1127–1134.
- [99] Wasserman P, Rubin DS. Highly prevalent vitamin D deficiency and insufficiency in an urban cohort of HIV-infected men under care. *AIDS Patient Care STDS.* 2010;24(4):223–227.
- [100] Rodríguez M, Daniels B, Gunawardene S, Robbins GK. High frequency of vitamin D deficiency in ambulatory HIV-Positive patients. *AIDS Res Hum Retroviruses.* 2009;25(1):9–14.
- [101] Wohl D, Doroana M, Orki C, Pilotto JH, Sungkanuparph S, Yeni P, Vanveggel S, Deckx H, Boven K. Change in vitamin D levels smaller, and risk of development of severe vitamin D deficiency lower, among HIV-1-infected, treatment-naive adults receiving TMC278 compared with efavirenz: 48-week results from the Phase III ECHO trial. Abstracts of the 17th Annual Conference of the British HIV Association (BHIVA), Bournemouth, UK, 2011.
- [102] Allavena C, Delpierre C, Cuzin L, Rey D, Viget N, Bernard J, Guillot P, Duvivier C, Billaud E, Raffi F. High frequency of vitamin D deficiency in HIV-infected patients: effects of HIV-related factors and antiretroviral drugs. *J Antimicrob Chemother* 2012; 67:2222-2230.
- [103] Brown T, MC Comsey G. Association between initiation of antiretroviral therapy with efavirenz and decreases in 25-hydroxyvitamin D. *Antivir Ther* 2010; 15: 425-429.
- [104] Fux CA, Baumann S, Furrer H, Muellaer NJ. Is lower serum 25-hydroxy vitamin D associated with efavirenz or the non-nucleoside reverse transcriptase inhibitor class? *AIDS* 2011; 25: 876-878
- [105] Welz T, Childs K, Ibrahim F, et al. Efavirenz is associated with severe vitamin D deficiency and increased alkaline phosphatase. *AIDS.* 2010;24(12):1923–1928.
- [106] Fox J, Peters B, Prakash M, Arribas J, Hill A, Moecklinghoff C. Improvement in vitamin D deficiency following antiretroviral regime change: Results from the MONET trial. *AIDS Res Hum Retroviruses.* 2011;27(1):29–34.
- [107] Fux Ca, Baumann S, Furrer H, Mueller Nj. Is lower serum 25-hydroxy vitamin D associated with efavirenz or the non-nucleoside reverse transcriptase inhibitor class? *AIDS* 2011; 25: 876-878.
- [108] Bech A, Van Bentum P, Telting D, Gisolf J, Richter C, De Boer H. Treatment of Calcium and Vitamin D Deficiency in HIV-Positive Men on Tenofovir-Containing Antiretroviral Therapy. *HIV Clinical Trials.* 2012; 13:350–356. [PubMed: 23195673]

- [109] Uzum AK, Salman S, Telci A, et al. Effects of vitamin D replacement therapy on serum FGF23 concentrations in vitamin D-deficient women in short term. *European Journal of Endocrinology*. 2010; 163:825–831. [PubMed: 20732956].
- [110] M. M. Roseninge, K. Gedela, A. J. Copaset al., “Tenofovirlinked hyperparathyroidism is independently associated with the presence of vitamin D deficiency,” *Journal of Acquired ImmuneDeficiencySyndromes*, vol.54,no.5,pp.496–499,2010.
- [111] P. Daria, C. Laura, R. Elena et al., “Secondary hyperparathyroidism in HIV patients: is there any responsibility of highly active antiretroviral therapy?” *AIDS*, vol. 25, no. 11, pp. 1430– 1433,2011.
- [112] C.K.Kwan,B.Eckhardt,J.BaghdadiandJ.A.Aberg,“Hyperparathyroidism and complications associated with vitamin D deficiencyinHIV-infectedadultsinNewYorkCity,NewYork,” *AIDSResearchandHumanRetroviruses*,vol.28,no.9,pp.1025– 1032,2012.
- [113] A. Bech, P. Van Bentum, D. Telting, J. Gisolf, C. Richter, and H. De Boer, “Treatment of calcium and vitamin D deficiency inHIV-positivemenontenofovir-containingantiretrovialtherapy,” *HIVClinicalTrials*, vol.13, no.6, pp.350–356,2012.
- [114] Heaney RP, Davies KM, Chen TC, Holick MF, Bargerlux MJ. Human serum 25-hydroxycholecalciferol response to extended oral dosing with cholecalciferol. *Am J Clin Nutr* 2003;77:204-210.
- [115] Van Bout-Van Den BeukelCJ, Van Den Bos M, OyenWJ, HermusAR, Sweep FC, Tack CJ, Bosch ME, Burger DM, Koopmans PP , Van DerVen AJ. The effect of cholecalciferol supplementation on vitamin D levels and insulin sensitivity is dose related in vitamin D deficient HIV-1-infected patients. *HIV Med* 2008;9:771-779.
- [116] Havens PL, Mulligan K, HazraR, Flynn P , Rutledge B, Van Loan MD, Lujan-Zilbermann J, Kapogiannis BG, Wilson CM, Stephensen CB, and the Adolescent Medicine Trials Network for HIV/AIDS Interventions (ATN). Serum 25-Hydroxyvitamin D response to vitamin D3 supplementation 50,000 IU monthly in youth with HIV-1 infection. *J ClinEndocrinolMetab* 2012; 97: 4004-4013.
- [117] Dr.ShubhadeepBhattacharjee, Effect of Vitamin-D, Zinc and Copper Supplementation in HIV-Positive Pregnant Women and Co-Relation with CD4 Counts- A Double Blinded Placebo Controlled Study, *International Journal of Science and Research (IJSR)*, 2013; ISSN (Online): 2319-7064.
- [118] Edgar T. Overton et al., High-Dose Vitamin D and Calcium Attenuates Bone Loss With ART Initiation: Results From ACTG A5280, ACTG A5280, PMID: 26075752, Dec 2015.
- [119] ElisabetLerma-Chippirrazetalet al., Validation Protocol of Vitamin D Supplementation in Patients with HIV-Infection. *AIDS Research and Treatment* Volume 2016, Article ID 5120831, <http://dx.doi.org/10.1155/2016/5120831>.
- [120] S. M. Arpadi, D. McMahon, E. J. Abramset al.,“Effect of bimonthly supplementation with oral cholecalciferol on serum 25-hydroxyvitaminDconcentrationsinHIV-infectedchildren and adolescents,”*Pediatrics*,vol.123,no.1,pp.e121–e126,2009.
- [121] S. Kakalia, E. B. Sochett, D. Stephens, E. Assor, S. E. Read, and A. Bitnun, “Vitamin D supplementation and CD4 count in children infected with human immunodeficiency virus,” *The Journal of Pediatrics*, vol.159, no.6, pp.951–957,2011.
- [122] Havens P, Hazra R, Stephensen C, Van Loan M, Rutledge B, Bethel J, Pan C, Liu N, Lujan-Zilbermann J, Mulligan K. Vitamin D3 supplementation decreases PTH in HIV-infected youth being treated with TDF-containing combination ART: a randomized, double-blind, placebo-controlled multicenter trial: Adolescent Trials Network Study 063. Abstracts from the 18th Conference on Retroviruses and Opportunistic Infections Boston, MA, 2011.
- [123] K.M.Sanders, A.L.Stuart, E.J.Williamsonetal., “Annualhighdose oral vitamin D and falls and fractures in older women: a randomized controlled trial,” *The Journal of the American MedicalAssociation*,vol.303,no.18,pp.1815–1822,2010.

- [124] M. R. Pinzone, M. di Rosa, M. Malaguarnera et al., “Vitamin D deficiency in HIV infection: an underestimated and undertreated epidemic,” *European Review for Medical and Pharmacological Sciences*, vol.17, no.9, pp.1218–1232,2013.

*Corresponding author.

E-mail address: vandana.dabla@ gmail.com